icon-    folder.gif   Conference Reports for NATAP  
  Conference on Retroviruses
and Opportunistic Infections (CROI)
February 22-25, 2016, Boston MA
Back grey_arrow_rt.gif
TAF / PrEP - TDF, TAF, Cabotegravir - Cabotegravir+Rilpivirine - LATTE-2, Maravoric / Dapivrine Vagnal Ring - Tenofovir Rectal / Long-Acting - MK-8591 Long Acting - BMS-986197
  Conference on Retroviruses and Opportunistic Infections (CROI) February 22-25, 2016, Boston MA
CROI: Switching tenofovir DF to tenofovir alafenamide in virologically suppressed adults....TAF/FTC Noninferior to TDF/FTC, and Safer, in Switch Study - Mark Mascolini - (02/25/16)
CROI: Switching to F/TAF (Tenofovir Alafenamide) from F/TDF (Tenofovir DF) based Regimen Study 311-1089: 48-Week Data - - (02/23/16)
CROI: Renal Safety of Tenofovir Alafenamide in Patients at High Risk of Kidney Disease - (03/05/16)
CROI: Longer-Term Safety of Tenofovir Alafenamide in Renal Impairment - (03/01/16)
CROI: Longer-Term Renal Safety of Tenofovir Alafenamide vs Tenofovir Disoproxil Fumarate - (03/01/16)
CROI: The Kidney Report - CROI 2016 - Christina Wyatt MD Associate Professor, Medicine/ Nephrology Icahn School of Medicine at Mount Sinai New York, NY (02/26/16)
CROI: It's Complicated: Renal Function & STIs in PrEP Users / Themed Discussion at CROI - (02/26/16)
CROI: Higher cumulative TFV/FTC levels in PrEP associated with decline in renal function - (02/26/16)
CROI: Recovery of bone mineral density after stopping oral HIV pre-exposure prophylaxis - (02/24/16)
CROI: Changes in Renal Function Associated with TDF/FTC PrEP Use in the US Demo Project - (03/08/16)
CROI: Quarterly STI Screening Optimizes STI Detection Among PrEP Users in the Demo Project - (03/08/16)
CROI: STI Data from Community-Based PrEP Implementation Suggest Changes to CDC Guidelines - (03/08/16)
CROI: 2 Dapivirine Vaginal Ring Studies - (03/07/16)
CROI: Dapivirine Vaginal Ring Cuts HIV Risk 27% to 56% in Two Trials in African Women - written by Mark Mascolini - (02/23/16)
CROI: Concentrations of TFV and TFVdp in Female Mucosal Tissues After a Single Dose of TAF - (03/08/16)
Dapivrine Vagnal Ring - Tenofovir Rectal
CROI: A Phase III Trial of the Dapivirine Vaginal Ring for HIV-1 Prevention in Women - (02/29/16)
CROI: Chemoprophylaxis with Oral FTC/TAF Protects Macaques from Rectal SHIV Infection - (02/29/16)
CROI: PrEP Impact on T cell Activation and Explant Infection...HPTN 069/ACTG 5305 Substudy - (02/29/16)
CROI: MTN-017: A Rectal Phase 2 Extended Safety and Acceptability Study of Tenofovir Reduced-Glycerin 1% Gel - (02/29/16)
CROI: Tenofovir Rectal Gel Safe and Acceptable in Study of MSM and TGW - Mark Mascolini - (02/25/16)
Cabotegravir PrEP - LATTE-2 Study - Long-Acting
CROI: ECLAIR: Phase 2A Safety and PK Study of Cabotegravir LA in HIV-Uninfected Men.......Long-Acting Cabotegravir Data Suggest PrEP Injections Every 8 Week - Mark Mascolini - (02/24/16)
CROI: Cabotegravir + Rilpivirine as Long-Acting Maintenance Therapy: LATTE-2 Week 32 Results - (02/24/16)
CROI: Injected Long-Acting Cabotegravir Protects Macaques From Injected SIV - Mark Mascolini - (02/25/16)
CROI: Cabotegravir Long-Acting Injection Protects Macaques against Intravenous Challenge - (02/26/16)
CROI: ViiV Healthcare announces first phase II HIV prevention study results for investigational long-acting injectable cabotegravir - (02/29/16)
Maraviroc PrEP
CROI: HPTN 069 / ACTG A5305 Phase II Study of Maraviroc (MVC)-Containing Regimens for HIV PrEP in Men Who Have Sex With Men (MSM) - (02/26/16)
CROI: Three Maraviroc PrEP Regimens Largely Protective in US MSM Study - Mark Mascolini - (02/24/16)
MK-8591 Long Acting - BMS-986197 Long-Acting with 3 Attachment Inhibitor Modes of Action
CROI: Long-Acting Oral and Parenteral Dosing of MK-8591 for HIV Treatment or Prophylaxis - (02/24/16)
CROI: A Single Monotherapy Dose of MK-8591,a Novel NRTI, Suppresses HIV for Ten Days - (02/24/16)
CROI: HIV Combinectin BMS-986197: A long-acting inhibitor with multiple modes of action - (02/29/16)